Transfer Factor Benefits: What Studies Report

"Transfer factor" is not one subject. In respiratory medicine the term refers to pulmonary transfer factor (TLCO, also written DLCO) — a physiological measurement of how efficiently carbon monoxide moves from inhaled gas into the blood. In immunology and in consumer supplement marketing, "transfer factor" refers to dialysable leukocyte extract, a low-molecular-weight preparation derived from white blood cells or colostrum that was investigated from the mid-twentieth century onward as an immune adjuvant. Searches for "transfer factor benefits" collect both meanings, so this page treats them separately and states, for each, what the published record in the citation set below actually measured.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health condition, test result or product. Nothing here describes a protocol, and no dose is given, because the verified literature summarised on this page does not report dosing information for transfer-factor preparations. Background on terminology and biology sits on the transfer factor overview.

How the evidence on this page is graded

Not all "studies" carry the same weight, and the difference matters more for transfer factor than for most topics, because much of the historical immunological work predates modern trial reporting standards.

Pulmonary transfer factor (TLCO): what the measurement literature reports

Standardisation of the test

The 2017 European Respiratory Society / American Thoracic Society technical standards for single-breath carbon monoxide uptake in the lung set out how the measurement should be performed, quality-controlled and reported (PMID 28049168). That document is a methods standard: researchers and clinical laboratories use it to make TLCO values comparable between devices and sites, and it does not evaluate any therapy. When a pulmonary report refers to "transfer factor", it is this standardised gas-uptake measurement — not a supplement.

TLCO as an outcome and as a prognostic marker

Because gas transfer reflects both lung architecture and pulmonary blood flow, studies in interstitial and pulmonary vascular disease frequently use it as an endpoint or predictor. A long-term cohort analysis in chronic hypersensitivity pneumonitis examined outcomes over extended follow-up and the clinical and physiological features associated with them (PMID 30515826). In chronic thromboembolic pulmonary hypertension, researchers analysed factors predicting outcome after pulmonary endarterectomy, a surgical procedure whose results are tracked with haemodynamic and gas-exchange measures (PMID 29927944). Both were observational; they describe associations within the populations studied rather than demonstrating that changing a single measurement changes a patient's course.

Interventions measured partly through lung function

A Cochrane systematic review assessed pulmonary rehabilitation for interstitial lung disease, pooling randomised trials that measured exercise capacity, symptoms and health-related quality of life (PMID 34559419); the review reported benefits on exercise capacity and quality-of-life measures in the shorter term, with less certainty about how long effects persisted. A 2025 analysis in Chest examined the relationship between pulmonary rehabilitation and survival in people with interstitial lung disease (PMID 39805518). Neither study tested a transfer-factor supplement; they are included here because they are the kind of research in which the phrase "transfer factor" legitimately appears, as a physiological variable.

Immune transfer factor (dialysable leukocyte extract): outcome domains studied

Oncology and adjuvant immunotherapy

Immune transfer factor was investigated during the era when non-specific immunostimulants were widely tested as adjuvants after cancer surgery. A review of adjuvant therapy of malignant melanoma surveyed the adjuvant approaches evaluated in that disease and the trial evidence behind them (PMID 12399001). Two Cochrane reviews of interventions for mycosis fungoides — the 2012 version (PMID 22972128) and its 2020 update (PMID 32632956) — systematically appraised randomised trials of treatments for this cutaneous T-cell lymphoma. These reviews describe the controlled-trial landscape for their conditions; this page does not attribute any transfer-factor-specific effect estimate to them, because effect sizes for individual agents are not stated in their title-and-abstract scope. Contemporary oncology reviews illustrate how far the field has moved toward molecularly targeted approaches: a 2024 review described advances in the diagnosis and treatment of MET-variant digestive tract tumours (PMID 39554732), a framework in which non-specific immunostimulants play no described role.

Infection prevention in immune-compromising conditions

One recurring claim is that transfer-factor preparations reduce infection rates in people with impaired immunity. The relevant controlled-evidence appraisal in this citation set is a Cochrane review of interventions for preventing infection in nephrotic syndrome, which evaluated randomised and quasi-randomised trials of preventive strategies in that population (PMID 22513919). The review's authors reported that the available trials were limited in number and quality, which is the general pattern for this question: the ambition of the research exceeded the size and rigour of the trials actually conducted.

Viral illness, including COVID-19

Interest in immune transfer factor resurfaced during the COVID-19 pandemic. A 2020 article in the Journal of Personalized Medicine set out postulated adjuvant therapeutic strategies for COVID-19 (PMID 32764275). The word postulated is doing real work: that paper proposed candidate adjuncts and the reasoning behind them rather than reporting outcomes from a controlled trial. Hypothesis papers of this kind generate testable questions; they do not establish that an intervention changed infection risk, severity or recovery.

Neurodevelopmental and "integrative medicine" claims

Transfer factor appears in older integrative-medicine literature on autism. A 2002 narrative article on medical management in autism reviewed a broad range of proposed interventions in a journal of complementary therapeutics (PMID 12495373). It was not a systematic review and did not report controlled outcome data, so it belongs in the "proposed, not tested" tier. Readers encountering transfer factor in autism discussions are generally encountering citations of this kind rather than randomised evidence.

Outcome domains at a glance

Claims the literature here does not support

Several popular "benefit" claims have no corresponding evidence in this citation set, and saying so is more useful than hedging:

• General "immune boosting" in healthy adults. None of the cited papers studied healthy-population immune endpoints; the closest controlled appraisal concerned infection prevention in a specific kidney disease (PMID 22513919).
• Fewer colds, faster recovery, or reduced respiratory infection frequency. The pandemic-era paper in this set was explicitly a postulated-strategy article (PMID 32764275), not an outcome trial.
• Energy, longevity, athletic performance or body composition. No study in this set measured these outcomes at all.
• Improved lung "transfer factor" from a supplement. The TLCO literature cited here concerns measurement standards (PMID 28049168) and rehabilitation programmes (PMID 34559419), not oral products.

Safety and Tolerability: What Studies Report

The verified papers summarised here do not report adverse-event data for transfer-factor preparations, and none states a dose, duration or administration route for such a product. Where safety appears in this citation set, it concerns other interventions: the Cochrane pulmonary rehabilitation review in interstitial lung disease considered harms alongside benefits in its appraisal of exercise programmes (PMID 34559419), and the perioperative analysis after pulmonary endarterectomy examined factors associated with outcome following major surgery (PMID 29927944). Absence of reported adverse events in a citation set is not the same as evidence of safety — it reflects that these particular studies were not designed to collect that information.

Interpreting the gap between claims and trials

Three structural issues explain why transfer factor remains poorly characterised despite decades of mention. First, naming overlap means that database hits for "transfer factor" are dominated by pulmonary physiology, where the term is formally defined (PMID 28049168). Second, much of the immunological work belongs to an adjuvant-immunostimulant era that was largely superseded by targeted and antigen-specific approaches, as contemporary oncology reviews illustrate (PMID 39554732, PMID 12399001). Third, where systematic reviewers have gone looking for controlled trials in the conditions most often cited, they have reported a thin and heterogeneous evidence base (PMID 32632956, PMID 22513919). Readers comparing a marketing claim with the literature will usually find that the claim sits in the hypothesis tier rather than the trial tier.

References

• 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung (The European Respiratory Journal, 2017)
• Pulmonary rehabilitation for interstitial lung disease (Cochrane Database of Systematic Reviews, 2021)
• Impact of Pulmonary Rehabilitation on Survival in People With Interstitial Lung Disease (Chest, 2025)
• Long-term outcomes in chronic hypersensitivity pneumonitis (Allergy, 2019)
• Factors predicting outcome after pulmonary endarterectomy (PLoS One, 2018)
• Interventions for mycosis fungoides (Cochrane Database of Systematic Reviews, 2020)
• Interventions for mycosis fungoides (Cochrane Database of Systematic Reviews, 2012)
• Adjuvant therapy of malignant melanoma (Critical Reviews in Oncology/Hematology, 2002)
• Interventions for preventing infection in nephrotic syndrome (Cochrane Database of Systematic Reviews, 2012)
• Postulated Adjuvant Therapeutic Strategies for COVID-19 (Journal of Personalized Medicine, 2020)
• Autism, an extreme challenge to integrative medicine. Part 2: medical management (Alternative Medicine Review, 2002)
• Advances in the diagnosis and treatment of MET-variant digestive tract tumors (World Journal of Gastrointestinal Oncology, 2024)